Side-by-side comparison

Tirzepatide vs Retatrutide

Dual versus triple incretin agonists in metabolic research. Receptor profile, molecular data and dose options compared.

Dual GIP/GLP-1 agonist — metabolic & glycaemic research.

Triple incretin agonist — next-gen metabolic research.

Specifications compared

Field	Tirzepatide	Retatrutide
Category	Weight Loss & Metabolic	Weight Loss & Metabolic
Sequence	GIP / GLP-1 dual receptor agonist	GIP / GLP-1 / glucagon triple agonist
CAS	2023788-19-2	2381089-83-2
Molecular weight	4813.5 g/mol	4731.4 g/mol
Purity	≥ 99.8 %	≥ 99.8 %
Doses available	10 mg, 30 mg, 60 mg	5 mg, 10 mg, 20 mg, 30 mg, 60 mg
Storage	Lyophilised: store at –20 °C, protected from light, up to 24 months. Reconstituted: keep at 2–8 °C and use within 14 days.	Lyophilised: store at –20 °C, protected from light, up to 24 months. Reconstituted: keep at 2–8 °C and use within 14 days.
Reconstitution	Reconstitute with bacteriostatic water (1–3 ml depending on the working concentration). Add slowly down the vial wall, then swirl gently — do not shake or vortex.	Reconstitute with bacteriostatic water (1–3 ml depending on the working concentration). Add slowly down the vial wall, then swirl gently — do not shake or vortex.

Tirzepatide

Retatrutide

For in-vitro research use only. This page compares product specifications and is not medical, clinical or dosing advice.